July 5, 2012

Mayo’s New Agreement Will Lead to First Commercialized Blood Test for Dementia


Mayo Clinic announced Tuesday that it has signed an agreement with Maryland-based A&G Pharmaceuticals that will ultimately pave the way for Mayo to offer the first commercial blood test to predict progranulin mutation status in patients suspected to havefrontotemporal dementia (FTD). Terms of the agreement were not disclosed.


MedCity News by Arundhati Parmar

Tags: A&G Pharmaceuticals, havefrontotemporal dementia, Industry News & Competitive Intelligence, Minnesota Partnership

Please sign in or register to post a reply.
Contact Us · Privacy Policy